Alpha psychiatry最新文献

{"title":"Effect of Paliperidone Combined with Sertraline in the Treatment of Schizophrenia and its Influence on Serum Neurofunctional Related Factors.","authors":"Meng Gu, Zhilian Pi, Long Zhu, Jun Zhang","doi":"10.31083/AP38775","DOIUrl":"10.31083/AP38775","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the efficacy of paliperidone combined with sertraline in treating schizophrenia (SCZ) and its effect on serum neurofunctional factors.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on SCZ patients admitted between June 2020 and June 2021. Initially, 80 patients were treated with paliperidone, while 36 received a combination of paliperidone and sertraline. Propensity score matching based on 3 covariates resulted in 2 groups: the control group (paliperidone alone, n = 36) and the observation group (paliperidone + sertraline, n = 36). The clinical efficacy, adverse reactions, quality of life scores, serum biomarkers levels related to nerve and liver function, and anxiety and depression levels were compared between the 2 groups.</p><p><strong>Results: </strong>The observation group demonstrated higher total effectiveness than the control group (<i>p</i> = 0.011). Post-treatment, the scores of all dimensions of quality of life in both groups were improved, and the observation group was higher than the control group (<i>p</i> < 0.001). Post-treatment, the observation group exhibited lower neuron-specific enolase (NSE) and higher neuregulin 1 (NRG1) levels than the control group (<i>p</i> < 0.001). The levels of aminotransferase (AST), total bilirubin (TBiL) and alanine aminotransferase (ALT) increased in both groups post-treatment (<i>p</i> < 0.001). The levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-2 (IL-2) decreased in both groups post-treatment, and the observation group had lower levels of these cytokines compared to the control group after treatment (<i>p</i> < 0.001). Post-treatment, Hamilton Anxiety Scale (HAMA) score and Hamilton Depression Scale (HAMD) score decreased in both groups, with the observation group showing lower scores than the control group (<i>p</i> < 0.001). The changes in the scores of various dimensions of quality of life, HAMA and HAMD scores, neurofunctional factors and inflammatory markers levels in the observation group were greater than those in the control group (<i>p</i> < 0.001). There were no serious side effects during and after treatment in both groups.</p><p><strong>Conclusions: </strong>Paliperidone combined with sertraline effectively improves serum neuregulin levels in SCZ patients, alleviates negative emotional effects without causing liver or kidney damage, and demonstrates excellent clinical efficacy and safety.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"26 1","pages":"38775"},"PeriodicalIF":1.3,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Children's Dietary Inflammatory Index with Depression and Anxiety Symptoms in Adolescents: Mediating Role of Inflammation and Cardiometabolic Risk Factors.","authors":"Kezban Şahin, Hülya Yardımcı, Murat Açık, Alkım Öden Akman, Fadime Yüksel","doi":"10.31083/AP38791","DOIUrl":"10.31083/AP38791","url":null,"abstract":"<p><strong>Background: </strong>Evidence is scarce on the mechanisms involved in the relationship between dietary inflammatory index and mental health in adolescents. This study aimed to assess the association between children-DII (C-DII) and depressive and anxiety disorder symptoms in adolescents and to explore whether inflammation and cardiometabolic risk factors mediate this association.</p><p><strong>Methods: </strong>The study was conducted at the Ankara City Hospital Pediatrics Polyclinic and 304 adolescents. In cross-sectional study, adolescents were asked general information questions. Anthropometric measurements were performed and some biochemical parameters and inflammation (C-reactive protein (CRP)) were obtained. The C-DII score was calculated from 24-h dietary recalls. Depression and anxiety levels of the participants were assessed by self-report. Structural equation modelling analyzed how cardiometabolic risk factors and inflammation mediate the relationship between mental health and dietary inflammation.</p><p><strong>Results: </strong>C-DII scores were positively associated with depression and anxiety score (β [95% confidence interval (CI)] = 0.224 [0.08-0.25] for depression; 0.923 [0.04-1.67] for anxiety). Except for dietary inflammation with anxiety in girls, these relationships remained statistically significant in all subgroups by sex. It was determined that CRP partially mediated the relationship between dietary inflammation and depression and anxiety. It was determined that body mass index (BMI)-z score and waist circumference (WC) mediated the relationship between dietary inflammation and depression scores.</p><p><strong>Conclusions: </strong>Our findings indicate that the higher pro-inflammatory potential of diet is associated with a higher risk of depression and anxiety, and this association may be mediated by CRP for depression and anxiety, WC, and BMI-z score for only depression. Further research is required to verify our findings and clarify the latent mechanism in larger populations.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"26 1","pages":"38791"},"PeriodicalIF":1.3,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-Analysis of the Clinical Efficacy of Auricular Acupressure on Patients with Depression.","authors":"Xiaohua Yang, Qingqing Liu, Xiaoping Wu","doi":"10.31083/AP38776","DOIUrl":"10.31083/AP38776","url":null,"abstract":"<p><strong>Objective: </strong>A systematic review of evaluating the clinical effects of auricular acupressure on patients with depression.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted in various electronic databases including PubMed, Web of Science, Cochrane Library, Google Scholar, CNKI, Wanfang, Embase, and VIP. The search time limit was from the establishment of the database to December, 2023. The included results were integrated and analyzed, and ReviewManager 5.4 was used for meta-analysis.</p><p><strong>Results: </strong>A total of 13 studies with a total of 504 depression patients were included. Compared with the control group, auricular acupressure showed a significant reduction in depression scores, as reflected in the Hamilton Depression Scale (standardized mean difference [SMD] = -1.50, 95% confidence interval [CI]: -2.25~-0.75); risk rate [RR] = 1.96, 95% CI: 0.66~5.82), Self-Rating Depression Scale (SMD = -0.91, 95% CI: -1.15~-0.67), and Patient Health Questionnaire scores (SMD = -0.94, 95% CI: -1.46~-0.41; all <i>p</i> < 0.01).</p><p><strong>Conclusions: </strong>The meta-analysis suggested that auricular acupoint therapy is safe and effective in treating depression, and can reduce Hamilton Depression Scale (HAMD) and Pittsburgh Sleep Quality Index (PSQI) scores. There were no obvious adverse reactions. This therapy could therefore be used as a complementary therapeutic approach for patients with depression.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"26 1","pages":"38776"},"PeriodicalIF":1.3,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prolactin-elevating Antipsychotics: Anti-hero or Savior?","authors":"Chong Guan Ng, Benedict Francis","doi":"10.31083/AP38785","DOIUrl":"10.31083/AP38785","url":null,"abstract":"","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"26 1","pages":"38785"},"PeriodicalIF":1.3,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Benzodiazepine and Z-Drug Prescriptions in Eastern China (2015-2021).","authors":"Qian Deng, Hualiang Chen","doi":"10.31083/AP38792","DOIUrl":"10.31083/AP38792","url":null,"abstract":"<p><strong>Objective: </strong>This study analyses trends in the prescription and usage of benzodiazepines (BZDs) and Z-drugs within specialised medical institutions and emergency outpatient services in China from 2015 to 2021, focusing on demographics and prescribing patterns to promote better management practices.</p><p><strong>Methods: </strong>A retrospective study was conducted from 2015 to 2021, reviewing prescription information and population characteristics from 10 hospitals, including specialised psychiatric institutions and general hospitals in Zhejiang, Jiangsu, and Shanghai. The study analysed a total of 33,569 valid prescriptions.</p><p><strong>Results: </strong>There was a noticeable increase in the total defined daily doses of both benzodiazepines and Z-drugs, with significant variations among different drugs. Lorazepam and zopiclone showed the most substantial increases in usage. Drugs like clonazepam and lorazepam were predominantly prescribed, indicating specific patterns in disease management, particularly for insomnia and anxiety.</p><p><strong>Conclusions: </strong>This study reveals a significant increase in benzodiazepine and Z-drug prescriptions, particularly among elderly and female patients. The findings highlight the need for targeted interventions and policy reforms to ensure safe prescribing practices and mitigate the risks associated with long-term use in these vulnerable populations.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"26 1","pages":"38792"},"PeriodicalIF":1.3,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations Between Delayed Sleep Phase Syndrome and Daytime Napping with the Metabolic Syndrome Among Adults: Results from the Ravansar Non-Communicable Disease (RaNCD) Cohort Study.","authors":"Niloofar Hemati, Ali Alipouriani, Mehdi Moradinazar, Alireza Ahmadi, Reza Mohammadi, Mitra Bonyani, Dena Sadeghi-Bahmani, Annette Beatrix Brühl, Habibolah Khazaie, Serge Brand","doi":"10.5152/alphapsychiatry.2024.241565","DOIUrl":"10.5152/alphapsychiatry.2024.241565","url":null,"abstract":"<p><strong>Objective: </strong>Adverse sleep and wake patterns are associated with physical health complaints, including metabolic disorders. The aim of this study was to evaluate the relationship between delayed sleep phase syndrome (DSPS) and napping during the day with metabolic syndrome (MetS).</p><p><strong>Methods: </strong>This study was conducted on 10 065 participants aged 35-65 years using baseline data from the Ravansar Non-Communicable Disease (RaNCD) cohort study. Delayed sleep phase syndrome was evaluated through a clinical interview to rule out the possibility that the sleep complaints were a result of psychiatric disorders. Logistic and linear regression models were used to determine associations.</p><p><strong>Results: </strong>The severity of MetS was found to be higher in men, older age groups, married people, subjects with a lower education level, urban residents, smokers, people with low physical activity, and DSPS. In the fully adjusted model, the odds of having MetS were 26% (95% Confidence interval (CI): 1.08, 1.48) higher in those with DSPS compared to those without DSPS. Additionally, the odds of MetS were 18% higher in people who napped less than 1 hour per day, 26% higher in those who napped 1-2 hours per day, and 21% higher in those who napped over 2 hours per day, compared to non-nappers. All of these associations were statistically significant. The odds of having the severity of MetS were significantly 6% (95% CI: 0.01, 0.12) higher in those with DSPS compared to those without DSPS.</p><p><strong>Conclusion: </strong>The findings of this study indicate that DSPS and daytime napping are associated with an increased risk of MetS. Interventions aimed at improving sleep quality are recommended as potential strategies to help reduce the risk of developing MetS.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"25 6","pages":"705-712"},"PeriodicalIF":1.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143016746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Evaluation of the \"Eating More Consciously\" Module of a Lifestyle Intervention Program to Prevent Medication-Induced Weight Gain in Psychiatric Patients: A One-Arm Pilot Study.","authors":"Catherine Glocker, Maria S Simon, Nicole Adler, Julia Eder, Barbara B Barton, Richard Musil","doi":"10.5152/alphapsychiatry.2024.241718","DOIUrl":"10.5152/alphapsychiatry.2024.241718","url":null,"abstract":"<p><strong>Objective: </strong>Overweight and obesity are health issues that are increasing worldwide. Patients with severe mental illness are particularly vulnerable for various reasons, including the intake of weight gain-associated drugs. In this pilot study, we targeted eating behavior as a predictor for medication-induced weight gain and developed a module of a prevention program (\"Eating More Consciously\") to be evaluated by psychiatric inpatients.</p><p><strong>Methods: </strong>Thirty-three patients participated in a behaviorally oriented group therapy program with 2 modules of 120 minutes each and weekly follow-up measurements over 4 weeks. Measures included weight, laboratory parameters, the German versions of the Three-Factor Eating Questionnaire (Fragebogen Essverhalten; FEV) and the Food Craving Inventory (FCI) as well as a questionnaire on the implementation of the strategies in everyday life.</p><p><strong>Results: </strong>Thirty-three participants completed both modules and felt that they had benefited from the module \"Eating More Consciously\". Fragebogen Essverhalten domain \"cognitive restraint\" scores increased significantly throughout the study (<i>P</i> = .039), and the FCI sum score decreased significantly (<i>P</i> = .003).</p><p><strong>Conclusion: </strong>We propose that the \"Eating More Consciously\" module is a promising approach to behavioral intervention in weight management in patients with severe mental illness. Prospective randomized controlled studies with a larger sample and a longer follow-up are needed.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"25 6","pages":"737-745"},"PeriodicalIF":1.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143016955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.5152/alphapsychiatry.2024.250001","DOIUrl":"https://doi.org/10.5152/alphapsychiatry.2024.250001","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.5152/alphapsychiatry.2024.241613.].</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"25 6","pages":"754"},"PeriodicalIF":1.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11736846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjunctive Intermittent Theta-Burst Stimulation for Schizophrenia: A Systematic Review and Meta-analysis of Randomized Double-Blind Controlled Studies.","authors":"Kai-Si Wen, Xin-Hu Yang, Nan Zhang, Si-Yuan Lin, Xing-Bing Huang, Todd Jackson, Yu-Tao Xiang, Wei Zheng","doi":"10.5152/alphapsychiatry.2024.241799","DOIUrl":"10.5152/alphapsychiatry.2024.241799","url":null,"abstract":"<p><strong>Objective: </strong>In order to determine whether intermittent theta-burst stimulation (iTBS) is a viable adjunct treatment for schizophrenia, a meta-analysis of double-blind, randomized clinical trials (RCTs) was performed.</p><p><strong>Methods: </strong>Four independent researchers extracted and synthesized data from RCTs on adjunctive iTBS for patients suffering from schizophrenia. RevMan 5.3 software was used to calculate risk ratios (RRs) and standardized mean differences (SMDs) along with their 95% confidence intervals (CIs).</p><p><strong>Results: </strong>Fifteen RCTs involving 671 patients with schizophrenia were included. Adjunctive iTBS was significantly superior to sham interventions for improvement in overall psychopathology (SMD = -0.75, 95% CI: -1.10, -0.41, <i>I</i> ² = 64%, <i>P</i> < .0001), negative symptoms (SMD = -0.76, 95% CI: -1.18, -0.35, <i>I</i> ² = 78%, <i>P</i> = .0003), and general psychopathology (SMD = -0.51, 95% CI: -0.88, -0.14, <i>I</i> ² = 71%, <i>P</i> = .007), though no significant group difference was found regarding positive symptoms. Adjunctive iTBS also demonstrated superiority over control treatments in improving cognitive functions as measured by the Spatial Span Test (SMD = 0.83, 95% CI: 0.16, 1.49, <i>I</i> ² = 73%, <i>P</i> = .02) and Montreal Cognitive Assessment (SMD = 0.49, 95% CI: 0.11, 0.88, <i>I</i> ² = 0%, <i>P</i> = .01). Discontinuation rates (RR = 0.92, 95% CI: 0.57, 1.50, <i>I</i> ² = 0%, <i>P</i> = .75) and adverse events were comparable between groups.</p><p><strong>Conclusion: </strong>The use of iTBS in patients with schizophrenia appears to be effective in improving psychiatric symptoms and cognitive function. To substantiate these preliminary findings, future research involving larger participant cohorts is warranted.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"25 6","pages":"676-684"},"PeriodicalIF":1.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143015728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Loneliness and Isolation in Psychiatric Perspective.","authors":"Fernando Lolas Stepke","doi":"10.5152/alphapsychiatry.2024.241808","DOIUrl":"https://doi.org/10.5152/alphapsychiatry.2024.241808","url":null,"abstract":"","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"25 6","pages":"748-749"},"PeriodicalIF":1.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}